TEM Tempus AI (TEM) Insider Trading, Ownership & Congress Trades
Software & IT · Services-computer programming, data processing, etc. · CIK 0001717115
Form 144 · 24
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
287
13F, latest reported quarter
What the filings say about TEM
Insiders, 180 days
-$105.9M net sold
9 sellers · 59% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: purchase, 2025-01-14
Planned sales (Form 144), 90 days
$71.4M
24 notices
Tempus AI insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Tempus AI, Inc. insiders sold a net $105.9M of stock across 555 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Aug 21, 2026.
- The trade is 13.4% of the 76,740 shares held after it.
- 5 other insiders sold within 30 days.
- 287 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, Diagnostics Schoenherr Thomas Edward sold about $873.9K of TEM under a 10b5-1 plan on Sep 25, 2026; 5 other insiders sold within 30 days and 287 funds added in the latest 13F quarter.Context
- 241 earlier Form 4 trades (code P or S) here by this insider (241 sales), the last on Sep 17, 2026.
- The trade is 0.1% of the 8,595,389 shares held after it.
- 5 other insiders sold within 30 days.
- 287 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman LEFKOFSKY ERIC P sold about $566.2K of TEM under a 10b5-1 plan on Sep 22, 2026; 5 other insiders sold within 30 days and 287 funds added in the latest 13F quarter.Context
- 241 earlier Form 4 trades (code P or S) here by this insider (241 sales), the last on Sep 17, 2026.
- The trade is 0.4% of the 8,561,619 shares held after it.
- 5 other insiders sold within 30 days.
- 287 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman LEFKOFSKY ERIC P sold about $2.6M of TEM under a 10b5-1 plan on Sep 22, 2026; 5 other insiders sold within 30 days and 287 funds added in the latest 13F quarter.Context
- 241 earlier Form 4 trades (code P or S) here by this insider (241 sales), the last on Sep 17, 2026.
- The trade is 0.2% of the 8,545,467 shares held after it.
- 5 other insiders sold within 30 days.
- 287 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman LEFKOFSKY ERIC P sold about $1.3M of TEM under a 10b5-1 plan on Sep 22, 2026; 5 other insiders sold within 30 days and 287 funds added in the latest 13F quarter.Context
- 241 earlier Form 4 trades (code P or S) here by this insider (241 sales), the last on Sep 17, 2026.
- The trade is 0.0% of the 8,545,283 shares held after it.
- 5 other insiders sold within 30 days.
- 287 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and Chairman LEFKOFSKY ERIC P sold about $14.5K of TEM under a 10b5-1 plan on Sep 22, 2026; 5 other insiders sold within 30 days and 287 funds added in the latest 13F quarter.555 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$105.9M over 180 days
-$72.0M over 90 days · -$88.0M of it by a 10%+ holder
below 91% of Software & IT
Congress
no House purchase disclosed in the last 12 months
Funds
287 funds bought in last quarter
more than 85% of Software & IT
Revenue
+83.4% year over year
more than 89% of Software & IT
Margin
-19.3% net margin
below 66% of Software & IT
Buybacks
no share repurchases reported
Short interest
21.6% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
What changed in the last 30 days
Sep 29CEO, Diagnostics Schoenherr Thomas Edward sold $873.9K under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch TEM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-17.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TEM: institutional holders (13F)
13F holdings, latest reported quarter
10,022,634 sh
$580.6M
8,291,053 sh
$480.3M
8,190,133 sh
$474.5M
5,405,406 sh
$313.1M
4,989,062 sh
$291.2M
Congress trades in TEM
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-01-14 · disclosed 3 days later
$50,001 - $100,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TEM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
THOMAS SCHOENHERR
Filed 2026-09-25
$845.5K
Eric Lefkofsky
Filed 2026-09-22
$19.5M
RYAN BARTOLUCCI
Filed 2026-09-17
$651.5K
Eric Lefkofsky
Filed 2026-09-17
$14.0M
ANDREW POLOVIN
Filed 2026-09-17
$206.5K
TEM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$102.2M position · as of 2026-07-31
6.6%
American Beacon ARK Transformational Innovation Fund
$10.4M position · as of 2026-06-30
6.5%
ARK Innovation ETF
$271.9M position · as of 2026-07-31
4.9%
REX IncomeMax Option Strategy ETF
$1.9M position · as of 2026-06-30
4.8%
Global X HealthTech ETF
$938.5K position · as of 2026-05-31
3.7%
AlphaCentric Robotics and Automation Fund
$869.0K position · as of 2026-06-30
3.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
14 registered trials, 10 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
13
Not applicable
10 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Health And Human Services
ADAPT CRO SUPPORT SERVICES SOLICITATION · 2025-09-18
$24.2M
Department Of Veterans Affairs
TASSO+ ASSAY TESTING FOR MVP PROGRAM · 2026-07-01
$8.4M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return · Eric Lefkofsky
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$41.5M
$67.9M
$7.3M
+47%
-37%
2024
$28.6M
$28.6M
$3.7M
-16%
-13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $105.9M sold by insiders over 180 days, 287 funds added last quarter, $71.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TEM financials
Revenue growth
+83.4%
XBRL, annual
Net margin
-19.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TEM
| FY Dec 2025 | $1.3B |
| FY Dec 2024 | $693.4M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $382.5M |
| Mar 2026 | $348.1M |
| Dec 2025 | $367.2M |
| Sep 2025 | $334.2M |
| Jun 2025 | $314.6M |
| Mar 2025 | $255.7M |
| Dec 2024 | $200.7M |
| Sep 2024 | $180.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-17.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TEM
| FY Dec 2025 | -19.3% |
| FY Dec 2024 | -101.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +1.5% |
| Mar 2026 | -36.2% |
| Dec 2025 | -14.7% |
| Sep 2025 | -23.9% |
| Jun 2025 | -13.6% |
| Mar 2025 | -26.6% |
| Dec 2024 | -6.5% |
| Sep 2024 | -41.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$263.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM TEM
| FY Dec 2025 | -$239.1M |
| FY Dec 2024 | -$211.2M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -$13.7M |
| Mar 2026 | -$81.5M |
| Dec 2025 | -$41.5M |
| Sep 2025 | -$126.5M |
| Jun 2025 | $36.6M |
| Mar 2025 | -$107.7M |
| Dec 2024 | -$47.2M |
| Sep 2024 | $48.6M |
At each fiscal year end
Single quarter
Debt to equity
0.42x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity TEM
| FY Dec 2025 | 0.42x |
| FY Dec 2024 | 2.99x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.42x |
| Mar 2026 | 0.48x |
| Dec 2025 | 0.42x |
| Sep 2025 | 0.43x |
| Jun 2025 | 0.73x |
| Mar 2025 | 0.72x |
| Dec 2024 | 2.99x |
| Sep 2024 | 3.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.26x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt TEM
| FY Dec 2025 | -1.05x |
| FY Dec 2024 | -1.12x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -1.26x |
| Mar 2026 | -0.93x |
| Dec 2025 | -1.05x |
| Sep 2025 | -1.01x |
| Jun 2025 | -0.23x |
| Mar 2025 | -0.83x |
| Dec 2024 | -1.12x |
| Sep 2024 | -1.09x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-67.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TEM
| FY Dec 2025 | -89.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -67.4% |
| Mar 2026 | -81.6% |
| Dec 2025 | -89.5% |
| Sep 2025 | -72.6% |
| Jun 2025 | -97.9% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-12.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TEM
| FY Dec 2025 | -15.3% |
| FY Dec 2024 | -94.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -12.7% |
| Mar 2026 | -16.5% |
| Dec 2025 | -15.3% |
| Sep 2025 | -12.5% |
| Jun 2025 | -16.0% |
| Mar 2025 | -46.0% |
| Dec 2024 | -94.7% |
| Sep 2024 | -76.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital TEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-17.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TEM
| FY Dec 2025 | -19.9% |
| FY Dec 2024 | -143.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -17.8% |
| Mar 2026 | -17.8% |
| Dec 2025 | -19.9% |
| Sep 2025 | -18.3% |
| Jun 2025 | -24.8% |
| Mar 2025 | -58.5% |
| Dec 2024 | -143.0% |
| Sep 2024 | -96.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing TEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value TEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield TEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing TEM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.3B | $693.4M | $531.8M | $320.7M |
| Operating income | -$252.9M | -$691.1M | -$196.1M | -$265.4M |
| Net income | -$245.0M | -$705.8M | -$214.1M | -$289.8M |
| EPS (diluted) | -1.41 | -6.23 | -4.20 | -5.30 |
| Operating cash flow | -$218.1M | -$189.0M | -$214.3M | -$168.2M |
| Cash | $604.8M | $341.0M | $165.8M | $302.9M |
| Long-term debt | $208.7M | $168.2M | $193.1M | n/a |
| Dividends paid | $0 | $5.6M | $5.6M | $5.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
TEM Stock Sonar score 6/7 axes
Find similar shapesCompareTEM ranks highest on growth (89th percentile) and institutional and government (47th), and lowest on insider conviction (6th), among Software & IT peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TEM filings, in plain words
Are Tempus AI insiders buying or selling TEM?
In the 180 days to 2026-10-28, Tempus AI insiders were net sellers, a net $105.9M across purchases and sales reported on Form 4, by 9 sellers.
Have members of Congress traded TEM?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Nancy Pelosi dated 2025-01-14.
Are there planned insider sales of TEM?
Yes. 24 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $71.4M of stock; the latest, by THOMAS SCHOENHERR, was filed 2026-09-25.
Read the full summary
In the 180 days to 2026-10-28, Tempus AI insiders were net sellers of TEM, a net $105.9M across purchases and sales reported on Form 4 by 9 sellers. Most of that figure, $88.0M, came from a holder of 10% or more rather than an officer or director. 59% of the 123 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in TEM, none in the last year; the latest on record is a purchase by Nancy Pelosi dated 2025-01-14. Insiders filed 24 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $71.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
